Prevalence and safety of diazoxide in the neonatal intensive care unit.

Published

Journal Article

OBJECTIVE: Diazoxide is used to treat infants with persistent hypoglycemia, but the prevalence of its use and adverse effects are not well described. We report demographic and clinical characteristics of infants treated with diazoxide in neonatal intensive care units (NICUs). STUDY DESIGN: Retrospective cohort study of infants 24-41 weeks' gestation admitted to 392 NICUs from 1997-2016, comparing characteristics between hypoglycemic infants exposed/not exposed to diazoxide. For diazoxide courses > 1 day, we report percentages of infants starting diuretics and/or developing new ventilator/oxygen requirement during therapy. RESULTS: Among 1,249,466 infants, 185,832 had hypoglycemia; 1066/185,832 (0.57%) received diazoxide. Diazoxide use increased over time (P = 0.001). Infants receiving diazoxide varied from 0-14.9% among centers. New diuretic courses were associated with 91/664 (14%), and new oxygen or ventilator requirement during therapy was associated with 64/556 (12%) and 34/647 (5%), respectively. CONCLUSIONS: Diazoxide use in NICU settings has increased over time. Infants receiving diazoxide commonly received diuretics.

Full Text

Duke Authors

Cited Authors

  • Gray, KD; Dudash, K; Escobar, C; Freel, C; Harrison, T; McMillan, C; Puia-Dumitrescu, M; Cotten, CM; Benjamin, R; Clark, RH; Benjamin, DK; Greenberg, RG; Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee,

Published Date

  • November 2018

Published In

Volume / Issue

  • 38 / 11

Start / End Page

  • 1496 - 1502

PubMed ID

  • 30206345

Pubmed Central ID

  • 30206345

Electronic International Standard Serial Number (EISSN)

  • 1476-5543

Digital Object Identifier (DOI)

  • 10.1038/s41372-018-0218-4

Language

  • eng

Conference Location

  • United States